This technology has the potential to edit genes in organisms to correct mutations at specific locations to treat genetic diseases and defects. The tool, otherwise known as “molecular scissors,” allows researchers to cut DNA at a specific location and modify existing genes. In June 2012, the two geneticists wrote a scientific paper describing a new tool capable of simplifying genome editing, a mechanism called CRISPR-Cas9. While these disputes are far from being resolved, recent developments suggest that most of the benefits of this invention may be slipping away from the two Nobel laureates.
It is not that simple, however: beyond the accolades, a legal battle has been ongoing for years over the intellectual property (IP) relating to the CRISPR‑Cas9 technology. One would think that the two award-winning scientists and the institutions to which they belong are poised to reap the huge economic rewards of their invention when its many applications are marketed throughout the world. This technology is at the source of a true biotechnological revolution that holds the promise of fabulous innovations in medicine, agriculture and many other fields. On October 7, 2020, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry to Professors Emmanuelle Charpentier and Jennifer Doudna for their immense contribution to the CRISPR‑Cas9 gene-editing technique.
